Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LGVN with free AI briefings, catalyst countdowns, and dilution alerts.

LGVN · Longeveron Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$18.1M Cash on Hand
10.8mo Cash Runway
Follow LGVN by email Get an email when LGVN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LGVN, unsubscribe in one click. Privacy

📣 What LGVN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Allogeneic Human Mesenchymal Stem Cells… Frailty Phase 1/2 · NCT02065245 Completed
Allogeneic MSC Mild Alzheimer's Disease Phase 2 · NCT05233774 Completed
Trivalent Influenza Vaccine Aging Frailty Phase 1/2 · NCT02982915 Completed
Lomecel-B medicinal signaling cells Hypoplastic Left Heart Syndrome Phase 2 · NCT04925024 Active not recruiting
Longeveron Mesenchymal Stem Cells HLHS Phase 1/2 · NCT03525418 Unknown
Penicillin Antibiotic Frailty Phase 1/2 · NCT02065245 Completed
Biological Challenge Agent Metabolic Disease Phase 2 · NCT02587572 Withdrawn
Allo-hMSCs Hypoplastic Left Heart Syndrome Phase 1 · NCT02398604 Terminated

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LGVN holds $18.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $5M/quarter from operations, an estimated runway of 10.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LGVN files for a raise →

Get the full LGVN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LGVN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.